Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83801 | 0.92 | KDM4E (0.43) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL5762917 | 0.90 | TAAR1 (0.38) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL82989 | 0.87 | TAAR1 (0.41) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL7664282 | 0.87 | MAOB (0.44) | MAPTNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL31323933 | 0.86 | ALDH1A1 (0.39) | MAPTALDH1A1 | |
| SCHEMBL6967654 | 0.84 | TAAR1 (0.44) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL83319 | 0.84 | NPC1 (0.46) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL8164187 | 0.84 | MAPT (0.46) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL8165766 | 0.84 | MAPT (0.46) | TAAR1MAPTNPC1RAB9AALDH1A1 | |
| SCHEMBL82386 | 0.84 | NPC1 (0.47) | TAAR1MAPTNPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8128943-B2 | Use of oxazole derivatives for controlling fish parasites | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | claimed |
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | claimed |
| EP-1931204-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | Novartis AG (CH) | 2008-06-18 | — | — | EP | claimed |
| WO-2007025694-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | claimed |
| US-8128943-B2 | Use of oxazole derivatives for controlling fish parasites | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-1931204-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1030850-B1 | AZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007025694-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | NOVARTIS AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20020137781-A1 | Preparation and use of enantiomer-pure 2,4-disubstituted oxazolines | FROELICH OLIVIER (FR) | 2002-09-26 | — | — | US | disclosed |
| US-6413912-B2 | AGRICULTURAL PESTICIDE | SYNGENTA CROP PROTECTION, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1165527-A1 | PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES | Novartis AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-20010011065-A1 | AZOLINE DERIVATIVES | SYNGENTA CROP PROTECTION, INC. (FORMERLY NOVARTIS CROP PROTECTION, INC.) | 2001-08-02 | — | — | US | disclosed |
| WO-2000058291-A1 | PESTICIDAL ENANTIOMER-PURE 2,4-DISUBSTITUTED OXAZOLINES | NOVARTIS AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| EP-1030850-A2 | AZOLINE DERIVATIVES | Novartis AG (CH) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999023081-A2 | TRIFLUOROMETHYLBIPHENYLYL-DIHALOPHENYLAZOLINES AS PESTICIDES | NOVARTIS AG (CH) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011065-A1 | AZOLINE DERIVATIVES | CRY1, CYP3A7, CYP11B1 | TAAR1 760/4885MAPT 222/4885NPC1 3236/4885 |
| US-20100303865-A1 | USE OF OXAZOLE DERIVATIVES FOR CONTROLLING FISH PARASITES | OXA1L, NPY5R, ZFX | TAAR1 2692/4885MAPT 4207/4885NPC1 3540/4885 |
| US-20020137781-A1 | Preparation and use of enantiomer-pure 2,4-disubstituted oxazolines | CYP1B1, CYP2S1, CHRM1 | TAAR1 1133/4885MAPT 4511/4885NPC1 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.